Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2025-03-17 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
上海浩欧博生物医药有限责任公司2024年年度财务报表
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets, income statements, cash flow statements, and changes in equity for the fiscal year 2024. It includes comprehensive financial data such as assets, liabilities, equity, revenues, expenses, and cash flows. The presence of notes and signatures of accounting officers further supports that this is a full financial report. The length of the document (15,000 characters) and the detailed financial data indicate this is not a mere announcement or certification but the actual report. The content matches the characteristics of an Annual Report (10-K) which covers the company's full financial performance for the year. FY 2024
2025-03-17 Chinese
四川敏医健康科技有限公司2024年年度财务报表
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets with assets, liabilities, and equity sections, along with notes to the financial statements. The presence of comparative figures for the current and previous year-end balances indicates it is a comprehensive financial report. The document length is about 15,000 characters, which is substantial and consistent with a full financial report rather than a brief announcement. There is no indication that this is a certification, announcement, or supplementary data. The content aligns with a full annual report containing financial statements and notes, typical of a 10-K or equivalent annual report filing. Given the detailed financial data and notes, the document is best classified as an Annual Report (10-K). Q1 2024
2025-03-17 Chinese
苏州西瑞玛斯化学品有限公司2024年年度财务报表
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheets, profit and loss statements, and cash flow statements with specific monetary amounts and accounting notes. It includes comprehensive financial data for a fiscal year, indicating it is a full financial report rather than a brief announcement or certification. The presence of detailed financial tables and notes strongly suggests this is an Annual Report (10-K equivalent) or a full-year financial report. There is no indication that this is a short quarterly or interim report, nor is it a mere announcement or certification. Therefore, the document is best classified as an Annual Report (10-K). FY 2024
2025-03-17 Chinese
湖南浩欧博生物医药有限公司2024年年度财务报表
Annual Report Classification · 100% confidence The document contains detailed financial statements including a balance sheet, income statement (profit and loss), and cash flow statement for the fiscal year ending December 31, 2024. It includes comprehensive financial data such as assets, liabilities, equity, revenues, expenses, and cash flows. The presence of full financial statements and notes indicates this is a comprehensive annual financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2024
2025-03-17 Chinese
江苏浩欧博生物医药股份有限公司关于召开2024年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2024 Annual General Meeting (AGM) of Jiangsu Haobo Biomedical Co., Ltd. It details the date, voting methods, meeting agenda including the review of the 2024 annual report, financial statements, profit distribution plan, and other proposals. It also includes instructions for shareholders on voting and attendance. The document does not contain the actual annual report or financial statements but is an announcement related to the AGM and the materials to be discussed there. The document length is 3471 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-03-17 Chinese
江苏浩欧博生物医药股份有限公司2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (立信会计师事务所) for the year 2024 audit work for 江苏浩欧博生物医药股份有限公司. It details the auditor's qualifications, independence, quality control, and audit work plan related to the 2024 annual audit. The document does not contain actual financial statements or detailed financial results but rather assesses the auditor's performance and quality management for the audit engagement. It is a standalone audit-related report focusing on the auditor's role and quality control rather than the full annual report or financial statements. The document length is 3480 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2024
2025-03-17 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.